Pioneering Stem Cell Therapy Research Halted
By Monya Baker of Nature magazineThe first company to test a human embryonic stem-cell product in patients has become the first big player to bail out of the field. Last week’s move shook investor confidence and raised questions about whether the company had overreached itself, as well as underscoring just how difficult novel therapies are to develop.Geron, based in Menlo Park, California, announced on November 14 that it would cease work on its stem-cell-therapy programmes to focus on its anti-cancer portfolio....